Vantage logo

Merck sees potential in Peloton 

Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…

Vantage logo

Déjà vu for Aveo and tivozanib

As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.